Lathrop & Gage LLP announced today that the firm has expanded its practice in biotechnology, pharmaceuticals and life sciences with the addition of two partners. Robert Anderson and Ken Zwicker, Ph.D., bring their global transactional and intellectual property expertise in the life sciences to the firm; augmenting the already robust life sciences IP practice of the firm’s Boston office, headed up by Giulio DeConti.
Prior to joining the firm, Anderson and Zwicker were key players in protecting and enabling Abbott Laboratories’ pharmaceutical products pipeline, particularly in the areas of biologics research and development and commercial manufacture, including Abbott’s drug, HUMIRA®, the first fully human therapeutic antibody. With more than thirty years of legal experience between them, Anderson and Zwicker have worked as a team for more than a decade in intellectual property assessment, protection, and licensing; bringing innovative biotechnology from concept to commercialization.
Anderson has extensive experience in global transactional law; including licensing, collaborative, clinical trial and mergers and acquisitions agreements. Before entering law, Anderson earned his bachelor of science in accounting from Villanova University, his master of science, in taxation from Bentley College, and he is also a certified public accountant. Anderson earned his juris doctorate and master of laws from Suffolk University Law School.
Zwicker is a patent attorney, with extensive experience in global patent strategy, protection, licensing, acquisition, and enforcement. Before entering law, he earned his bachelor of science in biology from Kent State University, his master of arts and Ph.D. in biology from Boston University, and conducted postdoctoral research at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology. He earned his juris doctorate from Suffolk University Law School.
“Bob and Ken’s experience base in the pharmaceutical area greatly expands our national footprint and our international presence in the thriving life sciences industry,” said Bill Rudy, chairman of Lathrop & Gage’s IP division. “Their experience handling intellectual property matters from concept to commercialization significantly enhances the firm’s intellectual property practice.”
